Trials / Recruiting
RecruitingNCT06561620
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
A Prospective Study of Befotertinib Adjuvant Therapy in Patients With Postoperative MRD-positive Non-small Cell Lung Cancer in Stage IA2-IB With High Risk Factors
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 592 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Befotertinib | Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor. |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2027-05-01
- Completion
- 2029-05-01
- First posted
- 2024-08-20
- Last updated
- 2024-08-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06561620. Inclusion in this directory is not an endorsement.